Literature DB >> 16786526

Significance of T2 lesions in multiple sclerosis: A 13-year longitudinal study.

Richard A Rudick1, Jar-Chi Lee, Jack Simon, Elizabeth Fisher.   

Abstract

OBJECTIVE: To evaluate the relation between T2 lesions and disease severity in relapsing-remitting multiple sclerosis (MS).
METHODS: This article describes a 13-year longitudinal study in 30 patients.
RESULTS: Patients were 36.3 +/- 6.0 years old, had MS for 6.1 +/- 5.8 years, Expanded Disability Status Scale was 2.2 +/- 0.8, and brain parenchymal fraction (BPF) was 0.825 +/- 0.015 at study entry. At last visit, Expanded Disability Status Scale was 4.4 +/- 1.95, Multiple Sclerosis Functional Composite was -0.34 +/- 1.7, and BPF was 0.774 +/- 0.037. Baseline T2 lesion volume correlated with the BPF of the last visit (r = -0.66; p < 0.0001), magnetization transfer ratio (MTR) in normal-appearing brain tissue (r = -0.52; p = 0.004), and lesion MTR (r = -0.76; p < 0.0001). Change in T2 lesion volume in the first 2 years correlated with BPF of the last visit (r = -0.40; p = 0.03), normal-appearing brain tissue MTR (r = -0.44; p = 0.015), lesion MTR (r = -0.46; p = 0.018), Multiple Sclerosis Functional Composite scores (r = -0.50; p = 0.005), and Paced Auditory Serial Addition Task scores (r = -0.52; p = 0.003). Age was a significant covariate for clinical but not magnetic resonance imaging outcomes.
INTERPRETATION: T2 lesions in relapsing-remitting MS correlate strongly with brain tissue loss and brain tissue integrity 13 years later, and with clinical disease severity, though age significantly impacts the clinical correlation. The results provide direct evidence for the disability threshold hypothesis in MS and support monitoring T2 lesions in relapsing-remitting MS.

Entities:  

Mesh:

Year:  2006        PMID: 16786526     DOI: 10.1002/ana.20883

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  31 in total

Review 1.  MRI in multiple sclerosis: what's inside the toolbox?

Authors:  Mohit Neema; James Stankiewicz; Ashish Arora; Zachary D Guss; Rohit Bakshi
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

Review 2.  Defining Disease Activity and Response to Therapy in MS.

Authors:  Ulrike W Kaunzner; Mais Al-Kawaz; Susan A Gauthier
Journal:  Curr Treat Options Neurol       Date:  2017-05       Impact factor: 3.598

Review 3.  MRI in the assessment and monitoring of multiple sclerosis: an update on best practice.

Authors:  Ulrike W Kaunzner; Susan A Gauthier
Journal:  Ther Adv Neurol Disord       Date:  2017-05-12       Impact factor: 6.570

Review 4.  Aggressive multiple sclerosis: proposed definition and treatment algorithm.

Authors:  Carolina A Rush; Heather J MacLean; Mark S Freedman
Journal:  Nat Rev Neurol       Date:  2015-06-02       Impact factor: 42.937

Review 5.  Current and Emerging Therapies in Multiple Sclerosis: Implications for the Radiologist, Part 2-Surveillance for Treatment Complications and Disease Progression.

Authors:  C McNamara; G Sugrue; B Murray; P J MacMahon
Journal:  AJNR Am J Neuroradiol       Date:  2017-04-20       Impact factor: 3.825

6.  Composite MRI scores improve correlation with EDSS in multiple sclerosis.

Authors:  A H Poonawalla; S Datta; V Juneja; F Nelson; J S Wolinsky; G Cutter; P A Narayana
Journal:  Mult Scler       Date:  2010-09       Impact factor: 6.312

7.  MR imaging intensity modeling of damage and repair in multiple sclerosis: relationship of short-term lesion recovery to progression and disability.

Authors:  D S Meier; H L Weiner; C R G Guttmann
Journal:  AJNR Am J Neuroradiol       Date:  2007 Nov-Dec       Impact factor: 3.825

8.  Omega-3 fatty acid supplementation decreases matrix metalloproteinase-9 production in relapsing-remitting multiple sclerosis.

Authors:  L Shinto; G Marracci; S Baldauf-Wagner; A Strehlow; V Yadav; L Stuber; D Bourdette
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2009-01-25       Impact factor: 4.006

9.  Clinical and conventional MRI predictors of disability and brain atrophy accumulation in RRMS. A large scale, short-term follow-up study.

Authors:  Sarlota Mesaros; Maria A Rocca; Maria P Sormani; Arnaud Charil; Giancarlo Comi; Massimo Filippi
Journal:  J Neurol       Date:  2008-07-03       Impact factor: 4.849

10.  Do positive or negative stressful events predict the development of new brain lesions in people with multiple sclerosis?

Authors:  M N Burns; E Nawacki; M J Kwasny; D Pelletier; D C Mohr
Journal:  Psychol Med       Date:  2013-05-17       Impact factor: 7.723

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.